Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens

NCT00419081 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

100

Enrollment

INDUSTRY

Sponsor class

Stopped Issues with Manufacturing

Conditions

Leukemia
Lymphoma

Interventions

DRUG: Forodesine Hydrochloride Sterile Solution, 5 mg/mL
DRUG: Forodesine Hydrochloride Capsules (100 mg)

Sponsor

BioCryst Pharmaceuticals